A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
Latest Information Update: 24 Jun 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 17 Jun 2025 Planned End Date changed from 15 Mar 2029 to 31 May 2028.
- 17 Jun 2025 Planned primary completion date changed from 15 Mar 2029 to 31 May 2028.
- 17 Jun 2025 Status changed from not yet recruiting to recruiting.